A Phase 4, Open-Label, Randomized Study of Two Inotuzumab Ozogamicin Dose Levels in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic leukemia Eligible for Hematopoietic Stem Cell Transplantation and Who Have Risk Factor(s) for Veno-Occlusive Disease.
- Fleming, Shaun Alan, (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research